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β2 microglobulines and expresses a secreted TNF-binding protein, TPV-2L or gp38, that displays
inhibitory properties against TNF from diverse mammalian species, including human, monkey, canine and
rabbit. TPV-2L also has sequence similarity with the MHC-class I heavy chain and interacts differently with
human TNF as compared to the known cellular TNF receptors or any of the known virus-encoded TNF
receptor homologs derived from many poxviruses. In order to determine the TNF binding region in TPV-2L,
various TPV-2L C-terminal truncations and internal deletions were created and the muteins were expressed
using recombinant baculovirus vectors. C-terminal deletions from TPV-2L resulted in reduced binding
afﬁnity for human TNF and speciﬁc mutants of TNF that discriminate between TNF-R1 and TNF-R2. However,
deletion of C-terminal 42 amino acid residues totally abolished the binding of human TNF and its mutants.
Removal of any of the predicted internal domains resulted in a mutant TPV-2L protein incapable of binding to
human TNF. Deletion of C-terminal residues also affected the ability of TPV-2L to block TNF-induced cellular
cytotoxicity. In addition to TNF, TPV-2L can also form complexes with human β2-microglobulin to form a
novel macromolecular complex. In summary, the TPV-2L protein is a bona ﬁde MHC-1 heavy chain family
member that binds and inhibits human TNF in a fashion very distinct from other known poxvirus-encoded
TNF inhibitors, and also can form a novel complex with the human MHC-1 light chain, β2-microglobulin.
© 2009 Elsevier Inc. All rights reserved.Introduction
Tumor necrosis factor (TNF), the prototype member of the TNF
superfamily of cytokines is an important immune regulator in
orchestrating early defense against viral infection (Benedict, 2003;
Benedict et al., 2003; Rahman and McFadden, 2006). The active pro-
inﬂammatory ligand is predominantly synthesized as a cell surface
homotrimer that can be cleaved and secreted from activated
macrophages and monocytes. The biological effects of TNF, mainly
to upregulate inﬂammation and apoptosis, are mediated by binding to
two receptors, TNF-R1 or TNF-R2, members of the TNF-R superfamily
of proteins (Aggarwal, 2003; Hehlgans and Pfeffer, 2005). The
interaction of TNF with any of the TNF-Rs activates a signaling cascade
leading to the triggering of downstream events that contribute to the
host anti-viral responses. As a counter-protection measure, many
viruses have acquired diverse strategies to manipulate TNF or TNF-
mediated responses. Some of the known anti-TNF viral immunomo-
dulatory molecules can directly bind and inhibit the function of TNFGenetics and Microbiology,
rcher Road, PO Box 100266,
ll rights reserved.ligandwhereas others modulate the TNF and TNF-R signaling pathway
(s) (Benedict et al., 2003; Rahman and McFadden, 2006).
Poxviruses encode a plethora of immunomodulators which are
important for evasion from host immune system (Nazarian and
McFadden, 2006; Seet et al., 2003). Among them, TNF inhibitors are
particularly vital for virus survival and most poxviruses have evolved
mechanisms to inhibit TNF and TNF-mediated signaling. For example,
poxviruses commonly express TNF modulators that can bind and
sequester extracellular TNF and inhibit TNF-R activation (Rahman and
McFadden, 2006). Two distinct types of poxvirus-encoded TNF
inhibitors have been identiﬁed so far, one groupmost closely resembles
secreted versions of the mammalian cell surface TNF-Rs, termed vTNF-
Rs, and the other group, exempliﬁed by TPV-2L,more closely resembles
the mammalian MHC class I heavy chain, termed vTNF-BPs.
Viral TNF inhibitors that resemble TNF-Rs display diverse ligand
binding speciﬁcities within the mammalian cytokines and chemo-
kines (Rahman and McFadden, 2006). vTNF-Rs can be further
subdivided into T2-like inhibitors encoded by the Leporipoxviruses
and the Crm (cytokine response modiﬁer) like inhibitors encoded by
the orthopoxviruses (Cunnion, 1999). The vTNF-Rs retain character-
istic CRDs (Cysteine rich domains) like their mammalian TNF-R
counterparts, but do not maintain a transmembrane anchoring
domain found in the cellular receptors. Myxoma virus-encoded
Fig. 1. Schematic representation of the TPV-2L constructs. (A) TPV-2L native protein (1–
338 amino acids) is shown with three hypothetical domains α1, α2 and α3; stars
showing the predicted N-glycosylation sites; grey boxes indicating the secretory leader
sequence; black boxes indicating the C-terminal acidic domain. The different C-terminal
deletion proteins are shown aligned with TPV-2L sequence, with rectangular boxes
terminating at the point of each truncation. (B) Schematic representation of the TPV-2L
internal deletion proteins; grey boxes indicating the secretory leader sequence; black
boxes indicating the C-terminal acidic domain.
463M.M. Rahman et al. / Virology 386 (2009) 462–468protein M-T2 also possesses characteristic CRDs and not only does the
secreted viral protein bind and inhibit rabbit TNF, but the intracellular
version of the viral protein can also inhibit apoptosis in virus-infected
lymphocytes (Schreiber et al., 1997). Further studies have found that
M-T2 also harbors a PLAD (PreLigand Assembly Domain) like-domain
present in cellular TNF-Rs (Sedger et al., 2006). The PLAD domain of
M-T2 can inhibit human TNF-R-mediated cell death by interaction
with the PLAD domains of both human TNF-R1 and TNF-R2 (Sedger et
al., 2006). Crm-like TNF inhibitors namely CrmB, CrmC, CrmD and
CrmE also possess multiple ligand binding properties. In case of CrmB
and CrmD the C-terminal domain (CTD) exhibits chemokine binding
properties, while the N-terminal domain retains the TNF binding/
inhibition properties (Alejo et al., 2006). In contrast, the shorter CrmC
and CrmE proteins which lacks CTD possess only TNF binding
properties. Among the orthopoxviruses, Cowpox virus (CPXV)
encodes all four Crm paralogues (Hu et al., 1994; Loparev et al.,
1998; Saraiva and Alcami, 2001; Smith et al., 1996). In contrast,
Ectromelia virus encodes only CrmD (Smith and Alcami, 2000) and
variola and monkeypox viruses encode CrmB only. The solved crystal
structure of CrmE from vaccinia virus strain Lister suggests that vTNF-
Rs most closely resemble mammalian TNF-R2 (Graham et al., 2007).
Some poxvirus family members, such as the Yatapoxviruses and
swine poxvirus, encode a unique class of TNF inhibitors, vTNF-BP,
which are very distinct from the vTNF-Rs or other cellular TNF-R
family members. Instead, the viral TNF-BPs share distant sequence
similarities with MHC class I heavy chain. The ﬁrst vTNF-BP was
identiﬁed from Tanapox virus (TPV), and is called gp38 or TPV-2L,
encoded by ORF 2L (Brunetti et al., 2003). Expressed TPV-2L protein
binds and inhibits human, monkey and canine TNF with very high
afﬁnity (Brunetti et al., 2003; Rahman et al., 2006). It was also
reported that the supernatants of TPV-infected cells contain protein
(s) that neutralize the biological activity of IL-2, IL-5, IFN-γ and TNF.
The activity responsible for this inhibitionwas originally designated as
gp38, based on its molecular mass of 38 kDa (Essani et al., 1994;
Paulose et al., 1998). However, the puriﬁed TPV-2L showed molecular
mass of about 45 kDa, inhibited only TNF and lacked any detectable
binding to IL-2, IL-5 and IFN-γ. One ortholog of this protein, YMTV-2L,
encoded by Yaba monkey tumor virus (YMTV) can also bind and
inhibit human and monkey TNF (Rahman et al., 2006). On the other
hand, the vTNF-BP protein from Swinepox virus exclusively binds and
inhibits only porcine TNF (Rahman et al., 2006). The vTNF-BPs were
shown to be biochemically distinct from the cellular TNF-Rs in terms
of binding to human TNF (hTNF). As shown with TPV-2L, hTNF
mutants that selectively bind to either TNF-R1 or TNF-R2 can still bind
toTPV-2L, but with different afﬁnities. This suggests that TNF and TPV-
2L interaction domains for binding to the cellular TNF-Rs are unique.
Here, we have characterized the human TNF binding properties of
TPV-2L by creating TPV-2L C-terminal and internal deletions. Our
results indicate that, except for the C-terminal 28 amino acids, the
bulk of the TPV-2L protein is critical for hTNF binding. TPV-2L also can
interact with human beta2-micoglobulin (hβ2m), in a fashion similar
to the cellular MHC class I heavy chain molecule, to form a novel viral-
host protein complex that we propose will have novel immunomo-
dulatory properties.
Results and discussion
Expression of TPV-2L deletion constructs using the baculovirus
expression system
TPV-2L and other members of vTNF-BPs exhibit distant similarity
with the α1, α2 and α3 domains of cellular MHC class I heavy chain
molecule. TPV-2L is a 338 amino acids long protein and has four
potential N-linked glycosylation sites (N22, N68, N99 and N213) but
no predicted O-linked glycosylation sites. This results in the expressed
TPV-2L protein having a higher observed molecular mass (approxi-mately 45 kDa) than calculated by just the amino-acid sequence
(38 kDa). The presence of N-linked glycosylation sites in TPV-2L has
been conﬁrmed by treating puriﬁed proteinwith Endo H and PNGase F
(data not shown). To assess any predicted protein–protein interaction
domain(s) that might interact with TNF or possibly other proteins, we
have created a series of C-terminal and internal deletions in TPV-2L
(Figs. 1A and B). Since TPV-2L is expressed as a secreted glycoprotein,
we left the N-terminal secretion signal sequence intact in all the
deletion constructs. The deletions are named according to the ﬁrst
amino acid codon deleted within the truncated protein and
encompass deletions ranging from 143 amino acids (TPV-2LΔK196)
to the deletion of only the C-terminal 11 amino acids (TPV-2L-ΔE328).
The C-terminal deletion TPV-2L proteins was expressed as Myc-His
tagged versions and also expressed using recombinant baculoviruses.
The expression of these TPV-2L deletion recombinant proteins was
conﬁrmed in the supernatants of the baculo-infected Sf21 cells. As can
be seen in Fig. 2A, the expression level of secreted protein was
different for each of the different C-terminal deletion constructs,
when equal amounts of supernatant were loaded. The native TPV-2L
and all the deletion constructs migrated with an apparent molecular
mass larger than that predicted from the amino acid sequence,
suggesting that these proteins were all glycosylated to some extent.
Deletion of 143 amino acids from the C-terminus (TPV-2LΔK196),
which removes the fourth predicted glycosylation site, did not affect
the secretion of the protein (Fig. 2A, lane 1). This indicates that at least
this CHO-modiﬁcation site does not have a major role in TPV-2L
expression level or secretion. However, when we pre-treated the cells
with tunicamycin, an inhibitor of N-linked glycosylation, the expres-
sion of the native as well as the truncated TPV-2L proteins were all
inhibited (data not shown).
In addition to the C-terminal deletions, several internal deletions
of TPV-2L were created; they are outlined in Fig. 1B. They were also
expressed as Myc-His tagged using baculovirus expression system.
The expression of the truncated proteins was checked from the
supernatant of the infected Sf21 cells. However, in some cases the
mutant TPV-2L protein secretion levels were severely reduced (Fig.
2B). Deletion between K196 and C297 residues did not affect the
secretion of expressed proteins and the level of secreted protein was
as robust as the native TPV-2L (Fig. 2B, lane 7). This further supports
the observation that the predicted fourth C-terminal glycosylation site
Fig. 2. Expression of TPV-2L deletion proteins. The baculovirus expressed Myc-His
tagged TPV-2L C-terminal deletion proteins (A) and internal deletion proteins (B) from
the infected Sf21 cell supernatants. Proteins were separated on a 10% polyacrylamide gel
and transferred to a PVDF membrane that subsequently was probed with mouse anti-
Myc antibody and HRP conjugated Goat anti-mouse antibody for detection. Lanes are as
marked and molecular size markers are indicated in kDa.
Fig. 3. Binding of TPV-2L mutants with hTNF and hTNF mutants. Over the immobilized
TPV-2L mutant proteins sensor chip surface was passed 100 μl of hTNF and hTNF
mutants. Sensograms showing the binding of hTNF and hTNF mutants, hTNF32/86 and
hTNF143/145 (50 nM each) to TPV-2L (A), TPV-2LΔE328 (B) and TPV-2LΔC311 (C)
analyzed by SPR (BIAcore X).
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However, deletion of N-terminal TPV-2L residues which cover the
predicted α2 and α3 domains severely reduced the secretion levels of
the expressed proteins (Fig. 2B, lanes 1–4).
Kinetic and afﬁnity analysis of TPV-2L deletions with hTNF and hTNF
mutants
To test whether the different TPV-2L deletion proteins can interact
with human TNF, screening was done by the Surface Plasmon
Resonance (SPR) method using Biacore X. The mutant myc-his tagged
proteins expressed in the baculovirus infected cell supernatant were
partially puriﬁed using metal afﬁnity resin. The proteins were then
individually immobilized at high density (∼2000–3000 RU) on NTA
sensor chips. Human TNF ligand was injected over the control (ﬂow
cell 1) and immobilized protein surface (ﬂow cell 2) in the chip.
Among various C-terminal deletion proteins the mutants which lack
11 (TPV2L-ΔE328) and 28 (TPV2L-ΔC311) amino acids, respectively,
retained efﬁcient TNF binding properties (Figs. 3B and C). However,
further deletion of 14 amino acids (TPV2L-ΔC297) essentially
abolished the TNF binding activity of the TPV-2L protein. None of
the other C-terminal deletion proteins bound to TPV-2L, although they
expressed and secreted as the native proteins (data not shown). None
of the internal 2L deletion proteinswere able to bind humanTNF (data
not shown). This suggests that only the C-terminal 28 amino acid
residues of TPV-2L protein are dispensible for TNF binding.
The TPV-2L deletion proteins which bound to human TNF were
further tested for their individual kinetic binding analysis. The
proteins were further puriﬁed using metal afﬁnity column and
independently immobilized at low densities (∼500 RU) on CM5
chips for kinetic and afﬁnity analysis. Different concentrations ofhumanTNF and humanTNFmutants were applied on the immobilized
mutant TPV-2L proteins. The TNF mutants used in this study are
R32W-S86T (hTNF32–86) and D143N-A145R (hTNF143–145), which
have different binding afﬁnities for TPV-2L and a related protein
YMTV-2L from YMTV (Rahman et al., 2006). The mutations are
located in or near the three loops (positions 30–36, 84–88, and 138–
150) important for interaction with TNF-Rs. Previous studies have
demonstrated that human TNFmutants R32W-S86T selectively bound
only to TNF-R1, whereas D143N-A145R bound only to TNF-R2
(Loetscher et al., 1993; Van Ostade et al., 1994). For kinetic analysis,
following an association period of 120 s, running buffer HBS-EP was
injected to monitor the dissociation phase of binding (Figs. 3B and C).
Kinetic analysis was performed as described before (Rahman et al.,
2006). Table 1 summarizes the kinetic binding parameters of TPV-2L
deletions with human TNF and TNF mutants. Deletion of 11 and 28
amino acid residues from C-terminus of TPV-2L had little effect on
interaction with native human TNF, as both the deletion proteins
bound to hTNF with high afﬁnity. However, deletion of these residues
severely reduced the binding and interaction with hTNF mutants.
None of the hTNF mutants bound to TPV-2L mutants which did not
interact with native hTNF. As reported before, hTNF32-86 had
signiﬁcantly reduced (14 fold) binding afﬁnity with TPV-2L than
native TNF (Rahman et al., 2006). This reduced binding was further
potentiated by deletion of TPV-2L C-terminal residues. In case of TPV-
Table 1
Kinetic binding parameters and afﬁnity constants of TPV-2L mutants to hTNF and hTNF
mutants
TPV-2L/mutants hTNF/mutants Ka (1/Ms) Kd (1/s) KD, nM Chi2
TPV-2L hTNF 5.26e6 2.25e−4 0.043 1.6
hTNF32-86 3.52e6 2.11e−3 0.600 1.4
hTNF143-145 7.76e6 1.37e−3 0.176 1.2
TPV-2LΔE328 hTNF 9.01e5 7.18e−5 0.08 1.8
hTNF32-86 5.86e6 5.02e−3 0.857 1.6
hTNF143-145 1.92e5 1.22e−4 0.637 1.9
TPV-2LΔC311 hTNF 1.56e6 1.67e−4 0.106 2.0
hTNF32-86 2.32e6 9.22e−3 4.0 1.4
hTNF143-145 6.6e5 5.99e−4 0.907 1.9
Association (Ka) and dissociation (Kd) rates as well as afﬁnity constants (KD) of TPV-2L
mutants for the hTNF and its mutants as determined by SPR are indicated.
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about 10-fold compared to the native TPV-2L (compare Figs. 3A and C
and Table 1). This reduction is partly because of slower association and
faster dissociation rate with TPV-2LΔC311 and further support the
interaction of mutant residues of TNF with C-terminus of TPV-2L.
However, deletion of C-terminal residues from TPV-2L had only
modest reduction in binding afﬁnity for hTNF143–145. C-terminal
deletion of 42 amino acids of TPV-2L protein completely abolished the
binding of both native and mutant form of TNF with TPV-2L.
Inhibition of human TNF mediated cytotoxicity by TPV-2L mutants
The inhibition of TNF-mediated biological activity by TPV-2L
deletion proteins was tested with a standard cytotoxicity bioassay
using murine L929 cells (Rahman et al., 2006). Sequential deletion of
C-terminal residues from TPV-2L also reduced the inhibitory activity
against hTNF gradually (Fig. 4). The IC50 of native TPV-2L to neutralize
hTNF is less than 1 nMbut in case of TPV-2LΔE328 and TPV-2LΔC311 it
increased to 4 and 8 nM, respectively. However, larger deletions of
TPV-2L lacked the ability to inhibit hTNF cytotoxity, in agreement with
the hTNF binding experiments. None of the internal deletions of TPV-
2L prevented hTNF mediated cytotoxity (data not shown).
Interaction of TPV-2L with human β2-microglobulin
Class I MHCmolecules are polymorphic glycoproteins composed of
a membrane bound variable heavy chain associated with a non-
polymorphic light chain, β2 microglobulin. In virus-infected cells,
MHC heterodimeric molecules bind peptides derived from viralFig. 4. Inhibition of TNF-mediated cellular cytotoxicity by TPV-2Lmutants. Crystal violet
staining was used to determine the percentage murine L929 cell viability after 12 h of
treatment with hTNF and increasing concentration of TPV-2L deletion proteins. The
values represent the median of three independent tests.proteins, which T cells recognize via their T-cell receptor chains
(Townsend and Bodmer, 1989). To counteract this, many viruses have
evolved mechanisms to regulate the function of class I MHC
molecules. For example, mouse and human cytomegaloviruses exploit
virus-encoded MHC class I homolog to protect the virus-infected cells
from killing. Like the cellular class I MHC heavy chain molecules, the
viral proteins also associate with β2m (Chapman and Bjorkman,1998;
Farrell et al., 1997). A human poxvirus, Molluscum contagiosum virus
(MCV), also encodes an MHC class I homolog (MC80R) and can form
complexes with β2m (Senkevich and Moss, 1998). Although TPV-2L
has relatively less sequence similarity with cellular MHC class I
molecule than the above examples, it has almost no similarity with
any other known viral orthologs of MHC class I molecules. To examine
whether this apparent difference is functionally signiﬁcant, we have
tested the ability of TPV-2L protein to interact with hβ2m. TPV-2L and
the deletion proteins were co-expressed with hβ2m using in vitro TnT
expression system (expressed from the T7 promoter present in theFig. 5. Interaction of TPV-2L with human β2-microglobulin. (A) TPV-2L deletion
proteins were co-expressedwith hβ2m using TnT system. The reactionwas incubated at
37 °C for additional 1 h and precipitatedwith Ni2+ beads. The samples were analyzed by
SDS-PAGE and Western blot for the presence of co-precipitating protein. (B) TPV-2L,
hβ2m and hα2Mwere co-incubated at 37 °C for 1 h, separated using non-reducing SDS-
PAGE and visualized byWestern Blot. Anti-myc antibody in the dilution of 1:5000 in 5%
milk in TBSwas used, followed by 1:5000 anti-mouse conjugatedwith HRP in 5%milk in
TBS. Molecular size markers are indicated in kDa.
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Since TPV-2L and the deletions all have His-tag at the C terminus, they
bound to the resin and the complex was detected using speciﬁc
antibody. Co-expression of TPV-2L and hβ2m resulted in the pull
down of hβ2m from the complex, as detected using anti-hβ2m
antibody (Fig. 5A, lanes 2 and 3). We also assessed the ability of TPV-
2L deletions to interact with hβ2m. TPV-2LΔE328 still has the ability
to interact with hβ2m but not in the case of TPV-2LΔC311 (Fig. 5A,
lanes 3 and 4). This suggests that unlike human TNF the amino acid
residues located between E328 and C311 are important for binding
with hβ2m. From this deletion studies it is also clear that the
mechanism of interaction for TNF and hβ2m with TPV-2L could be
different.
In order to conﬁrm the complex formation between TPV-2L and
hβ2m a gel-shift experiment was performed (Fig. 5B). TPV-2L
protein alone, or together with hβ2m with or without human alpha
2 macroglobulin (hα2M), are co-incubated at 37 °C for 1 h. TPV-2L
alone produced no shifted complex but in contrast, a high molecular
weight complex appeared when TPV-2L and hβ2m were co-
incubated indicating binding of the two proteins into a larger
complex (Fig. 5B, lane b). The presence of hβ2m in the higher
molecular mass was also conﬁrmed with antibody against hβ2m
(data not shown). When TPV-2L was co-incubated with hα2M, there
was no interaction (Fig. 5B, lane c) but, interestingly, when TPV-2L,
hβ2m and hα2M (lane d) were combined, a distinct higher
molecular mass species was detected. Again, the presence of hα2M
in this higher molecular mass was conﬁrmed with antibody against
hα2M (data not shown). However, the gel conditions do not reﬂect
the actual sizes of the complexes (Fig. 5B, lanes b and d). As a
control, hα2M alone or TPV-2L co-incubated with heparin did not
show any obvious shifted complex in the gel. This result suggests
that TPV-2L alone can interact with hβ2m but not with hα2M, as
indicated by the shift to a higher molecular mass. However, when
TPV-2L is bound with hβ2m, then this complex is now able to
interact with hα2M. Further suggesting that the ordered sequence of
protein binding (TPV-2L-hβ2m ﬁrst, and then hα2M) is important
for the interaction of TPV-2L. It has been reported that β2m has the
capacity to bind to α2M, a serum anti-protease (Gouin-Charnet et
al., 2000). There is further evidence that α2M with some
conformational change, acquires the ability to bind a variety of
cytokines such as IL-2, IFN-γ and TNF-α (James et al., 1992; Legres et
al., 1995). TPV may gain additional anti-immune arsenal from such
interactions.
Materials and methods
Reagents and cells
Recombinant human TNF, human IL-2, human IL-5, and human β2
microglobulin, were obtained from R and D biosystems, human α2
macroglobulin was obtained from Fitzgerald Industries International
Inc. Human TNF mutants hTNFR32W-S86T and hTNFD143N-A145R
were produced as described before (Rahman et al., 2006). Sf21 cells
(Invitrogen) were cultured in SF-900 II serum-free medium (Invitro-
gen) and grown at 27 °C. Mouse L929 cells were cultured in DMEM
(Dulbecco's Modiﬁed Eagle's Medium) supplemented with 10% fetal
bovine serum.
Generation of TPV-2L deletion constructs for protein expression in the
baculovirus system
The TPV-2L deletion constructs weremade using polymerase chain
reaction (PCR) and oligonucleotides. The plasmid, pcDNA-TPV-2L
containing the complete TPV-2L open reading frame was used as
template (Brunetti et al., 2003). The desired deleted sequences werePCR ampliﬁed with speciﬁc oligonucleotides (Supplementary Table
S1) and Pfu DNA polymerase (Stratagene) using TPV-2L as template.
PCR ampliﬁed DNAwas digested with EcoRI and XhoI and cloned into
pcDNA3.1/Myc/His (Invitrogen) plasmid in order to make C-terminal
Myc and His6 fusion. The correct sequence of all the cloned DNA
fragments was conﬁrmed by DNA sequencing.
Internal deletions of TPV-2L were made by ampliﬁcation of two
fragments lacking the deleted region and the two fragments were
annealed and reampliﬁed using the N-terminal and C-terminal
primers of the gene. PCR was used to amplify the upstream and
downstream regions of the desired deletion sequences with speciﬁc
oligonucleotides and pfu DNA polymerase using TPV-2L sequence. The
primer pairs for internal deletions are presented in Supplementary
Table S1. Products from the two PCR reactions were puriﬁed using
agarose gel electrophoresis and the two products with overlapping
termini were mixed, denatured by heating to 95 °C and allowed to re-
anneal. DNA polymerase and dNTPs were added for 3′ extension of the
overlapping termini, followed by a second round of PCR ampliﬁcation
of the full length extension using TPV-2L forward and reverse primers.
The products were digested with EcoRI and XhoI and cloned in
pcDNA3.1/Myc/His to make C-terminal Myc and His6 fusion. Using
the same method all other deletion constructs were made. All clones
were sequenced to ensure that mutations had not been introduced
during the ampliﬁcation. The deleted clones were further transferred
in pFastBac1 (Invitrogen) plasmid.
Generation of recombinant baculoviruses
The TPV-2L deletions and truncations in pcDNA3.1 plasmid were
transferred into pFastBac1 plasmid (Invitrogen) and recombinant
baculoviruses were produced using the Bac-to-Bac expression system
following the manufacturers protocols (Invitrogen). Brieﬂy, the
plasmids were transformed into competent DH10Bac bacteria,
where a transposition event generated the corresponding recombi-
nant bacmids. The puriﬁed bacmid DNA were transfected into Sf21
insect cells and the recombinant baculoviruses were harvested from
the cell culture supernatants 3–5 days after transfection. These viruses
were further ampliﬁed in one step to generate a higher titer
recombinant virus stock for protein production.
Protein puriﬁcation
For protein expression Sf21 cells were infected with recombinant
baculoviruses at high MOI of 5–10 pfu/cell. Cell supernatants were
harvested at 3–4 days postinfection (pi), clariﬁed by centrifugation at
2000 ×g for 10 min followed by high speed at 30,000 ×g for 30 min
and then concentrated 10-fold using protein concentrator (Pall Life
Sciences). The concentrated supernatants were then buffer-
exchanged against phosphate buffer, pH 7.0, containing 10 mM
imidazole. Protein was puriﬁed by metal chelate afﬁnity chromato-
graphy (Ni2+/Co2+) following the manufacturer's protocol (Invitro-
gen). Puriﬁed protein was analyzed by 10% acrylamide SDS-PAGE
stained with Coomassie Blue R250. The protein concentration was
measured by the Bradford assay or absorbance measurements at
280 nm.
Cytolytic assays
Mouse L929 cells were used to test TNF-mediated cytotoxicity
using a crystal violet staining method (Rahman et al., 2006). In this
method 105 cells per well were seeded in 12-well plates in a total
volume of 500 μl of cell growth medium (DMEM with 10% FBS) and
incubated overnight at 37 °C. The next day the medium was removed
and cells were treated with medium containing 5 μg/ml actinomycin
D and 1 ng/ml human TNF in the presence or absence of serial
dilutions of TPV-2L proteins. The cells were incubated for 18 h at 37 °C,
467M.M. Rahman et al. / Virology 386 (2009) 462–468washed three times with PBS and stained for 10 min with 200 μl of
0.5% crystal violet in water. Plates were washed with water and the
dye was solubilized with 2% sodium deoxycholate and the absorbance
(A) was determined at 570 nm. All assayswere performed in triplicate.
Percentage of cytolysis was quantiﬁed by following equation:
kC= A control wellð Þ− A testð Þ
 
= A control wellð Þ
 
×100:
Analysis of TNF binding speciﬁcity and afﬁnity constants
TNF binding speciﬁcity and afﬁnity constants were estimated by
Surface PlasmonResonance (SPR) using a BiacoreXbiosensor (Biacore,
GE Healthcare). Screening of TNF binding was done using the NTA
sensor chip (Biacore) as described before (Rahman et al., 2006). In
brief, the sensor chip surfacewas activated with 500 μMNiCl2 solution
in eluent buffer followed by immobilization of the protein by injection
of 50 nM His-tagged protein at a ﬂow rate of 2–5 μl/min until the RU
(Response Difference) reached N3000. Tomonitor the binding, human
TNF was injected at a rate of 30 μl/min for 3 min. The sensor chip
surface was regenerated by stripping nickel from the surface by
injection of regeneration solution containing EDTA.
Kinetic analysis of the recombinant TPV-2L proteins was done by
standard amine coupling chemistry using CM5 chips. The proteins
were immobilized at low densities of 500 RU and different
concentrations of hTNF were injected at a ﬂow rate of 50 μl/min
over a period of 2 min and allowed to dissociate for an additional
5min by allowing the buffer to ﬂow. The surfacewas regenerated after
each injection using 10 mM acetate pH 4.0 or 10 mM glycine–HCl pH
1.5. The data were analyzed globally with the BIAevaluation 3.0
software by using a 1:1 Langmuir model.
Immunoblotting
Protein samples were separated on SDS-PAGE gels and transferred
to PVDF membrane (GE Healthcare) using a semidry transfer
apparatus (Biorad). Membranes were blocked in TBST (20 mM Tris,
150 mM NaCl, 0.1% Tween-20 pH 7.6) containing 5% non-fat dry milk
for 1 h at room temperature and then incubated with primary
antibodies mouse anti-myc (Santa Cruz), mouse anti-h β2m (Santa
Cruz) overnight at 4 °C. The membranes were washed three times for
10 min each with TBST and incubated with goat-anti-mouse-HRP as
secondary antibody in TBST containing 5% non-fat dry milk for 1 h at
room temperature with gentle agitation. The membrane was washed
three times for 10 min each with TBST, and the signal was detected by
applying chemiluminescence substrate (Pierce) and exposed to x-ray
ﬁlm (Eastman Kodak).
In vitro transcription/translation of plasmid constructs and pull-down
experiments
The rabbit reticulocyte coupled transcription and translation (TnT)
system (Promega) was used according to manufacturer's protocol for
expression of proteins in vitro. Protein expression was conﬁrmed by
running 2.5 μl of the TnT reaction on SDS-PAGE gels and western blot
analysis using anti-myc antibody (Santa cruz) for the Myc-His tagged
protein and speciﬁc antibody for the untagged proteins. For pull-down
the two plasmids were co-expressed using TnT in 10 μl reaction. 2 μl of
the reaction was used for conﬁrming protein expression by Western
blot analysis. Remaining of the reaction was incubated at 37 °C water
bath for 1 h for the formation of protein complex. For pull-down, Ni2+
beads (20 μl) were equilibrated in binding buffer (50mMNaH2PO4, pH
8.0, 500 mM NaCl and 20 mM imidazole) and added to the protein
complex followed by incubation for 4 h at 4 °C. The beads were
collected by centrifugation (60 s, 3000 rpm), the supernatant was
discharged and the beads were subsequently washed there times with300 μl of binding buffer. The bound proteins were eluted from the
beads with SDS-PAGE sample buffer and analyzed by SDS-PAGE and
Western blot analysis.
TPV-2L co-incubation experiment
The TPV-2L protein containing baculovirus supernatant (5 μL) or
puriﬁed TPV-2L protein (1 μg/μl) was incubated with 1 μL of human-
β-2 microglobulin (1 μg/μL in PBS) or 1 μL of human-α-2
macroglobulin (1 μg/μL in PBS), alone or in combination of both the
proteins in a volume of 10 μl for 60 min in a 37°C water bath. Sterile
PBS was added to achieve consistent sample volume prior to the
addition of equal volume of SDS-gel loading buffer (20% Glycerine,
4.6% SDS, 0.002% bromophenol blue) without reducing agent. A
sample of 3 μL of sodium heparin (1 μg/μL in PBS, Sigma), mixed with
TPV-2L protein was used as a control. Samples were separated on a
10% Tris–Glycine gel at a constant 100 V for 2 h 30min and detected by
Western blot analysis.
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